ONO Pharmaceutical Co. Ltd. has agreed to acquire all outstanding shares of Deciphera Pharmaceuticals Inc. (Nasdaq: DCPH), a biopharmaceutical company focused on discovering new medicines for people with cancer, followed by a merger of Deciphera with a subsidiary of ONO for $2.4 billion.
Together, ONO and Deciphera will drive their vision to deliver new drugs and serve patients around the world. Deciphera brings research and development (R&D) capabilities in kinase drug discovery, commercial and sales platforms in the United States and Europe and global clinical development capabilities. The deal looks to help ONO build a presence in oncology and also support ONO’s efforts to become a global specialty pharma company.
JPMorgan Securities LLC is serving as financial advisor to Deciphera and Goodwin Procter LLP is serving as legal counsel. BofA Securities is serving as financial advisor to ONO and Greenberg Traurig is serving as legal counsel.